Iteos Therapeutics Inc (ITOS) Return on Investment ROI from the second quarter of 2025 to second quarter of 2024 and for the year 2025, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Iteos Therapeutics Inc   (NASDAQ: ITOS)


Iteos Therapeutics Inc's ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Iteos Therapeutics Inc's ROI in the second quarter of 2025?
Iteos Therapeutics Inc recorded a cumulative net loss of $-202 million during 12 months ending in the second quarter of 2025, resulting in a negative return on investment (ROI) of -33.45%.

Within the Healthcare sector 387 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2025 from 363 to 3313.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Investment Change TTM -3.62 % 3.65 % -1.12 % -4.96 % -6.97 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 544 591 622 663 692
Return On Investment (TTM) -33.45 % -20.37 % -21.04 % -19.09 % -17.23 %
ITOS's Overall Ranking # 3313 # 363 # 2631 # 2945 # 3114
Seq. Investment Change TTM -5.77 % 0.52 % 0.58 % 1.16 % 1.34 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -202 -131 -134 -121 -108

ITOS Company Profile >> Back to ITOS Roi Comparisons >> See Annual ITOS Return On Investment



Return On Investment ITOS's Ranking
Within: No.
Industry # 47
Sector # 388
Overall # 3313

Return On Investment Statistics
High Average Low
62.29 %
1.06 %
-48.66 %
(Mar 31 2022)   (Jun 30 2020)



  News about Iteos Therapeutics Inc Return on Investment ROI

iTeos Therapeutics Promising Lung Cancer Breakthrough Tempered by Market Headwinds,

September 14, 2024

iTeos Therapeutics Reports Promising Results in Lung Cancer Study Amid Market ChallengesiTeos Therapeutics Inc. has recently announced encouraging findings from its GALAXIES Lung-201 study, which investigated the combination of belrestotug and dostarlimab as a first-line treatment for patients with non-small cell lung cancer (NSCLC) characterized by high PD-L1 expression. This interim analysis has revealed clinically meaningful response rates across all dose levels investigated, which raises hopes for this treatment regimen in a patient population where treatment options can be limited.The GALAXIES Lung-201 study is designed to assess the safety and efficacy of belrestotug, a novel immunotherapy aimed at enhancing anti-tumor immune response, in combination with dostarlimab, a well-established PD-1 inhibitor. The interim analysis highlights that patients receiving treatment have shown positive clinical responses, suggesting a potential benefit for those battling advanced NSCLC.





Financial Statements
Iteos Therapeutics Inc's II. Quarter Investments $ 544 Millions ITOS's Balance sheet
Iteos Therapeutics Inc's II. Quarter Income $ -79 Millions Quarterly ITOS's Income Statement
ITOS's Income by Division See ITOS's Income by Division


ITOS Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 622 607 696 581 330
Y / Y Investment Growth 2.44 % -12.76 % 19.8 % 76.17 % -
Net Income in Millions -134 -113 97 215 -38
Y / Y Net Income Growth - - -54.95 % - -
Annual Return On Investment -21.62 % -18.56 % 13.9 % 36.95 % -11.54 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ITOS's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ITOS's Competitors
Subscribers only: Roi for Iteos Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ITOS's Customers

Other Ratios
ITOS's Roa ITOS's Inventory Turnover Ratio ITOS's Growth Rates ITOS's Dividend Statistics
ITOS's Profitability Ratios ITOS's Asset Turnover Ratio ITOS's Dividend Growth
ITOS's Roe ITOS's Valuation Ratios ITOS's Financial Strength Ratios ITOS's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector ROI

Date modified: 2026-09-08T15:22:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.